An Open-Label, Multicenter Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of TA-7284 in Subjects With Type 2 Diabetes Mellitus.
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2015
At a glance
- Drugs Canagliflozin (Primary) ; Antihypercalcaemics
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Registrational
- Sponsors Mitsubishi Tanabe Pharma Corporation
- 07 Jun 2017 Biomarkers information updated
- 03 Nov 2015 Results of post-hoc subgroup analyses (n=1299) published in the Advances in Therapy
- 01 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.